🚀 VC round data is live in beta, check it out!
Inovio Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Inovio Pharmaceuticals and similar public comparables like Ovid Therapeutics, Bioceltix, Equillium, Cantargia and more.
Inovio Pharmaceuticals Overview
About Inovio Pharmaceuticals
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Founded
1983
HQ
Employees
134
Website
Sectors
Financials (LTM)
EV
$78M
Inovio Pharmaceuticals Financials
Inovio Pharmaceuticals reported last 12-month revenue of $2M.
In the same LTM period, Inovio Pharmaceuticals generated $2M in gross profit and had net loss of ($83M).
Revenue (LTM)
Inovio Pharmaceuticals P&L
In the most recent fiscal year, Inovio Pharmaceuticals reported revenue of $65K and EBITDA of ($82M).
Inovio Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $65K | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($82M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (125426%) | XXX | XXX | XXX |
| EBIT Margin | (3622%) | XXX | (132864%) | XXX | XXX | XXX |
| Net Profit | ($83M) | XXX | ($85M) | XXX | XXX | XXX |
| Net Margin | (3555%) | XXX | (130000%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Inovio Pharmaceuticals Stock Performance
Inovio Pharmaceuticals has current market cap of $119M, and enterprise value of $78M.
Market Cap Evolution
Inovio Pharmaceuticals' stock price is $1.73.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $78M | $119M | 0.0% | XXX | XXX | XXX | $-1.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInovio Pharmaceuticals Valuation Multiples
Inovio Pharmaceuticals trades at 33.3x EV/Revenue multiple, and (1.0x) EV/EBITDA.
EV / Revenue (LTM)
Inovio Pharmaceuticals Financial Valuation Multiples
As of March 18, 2026, Inovio Pharmaceuticals has market cap of $119M and EV of $78M.
Equity research analysts estimate Inovio Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inovio Pharmaceuticals has a P/E ratio of (1.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $119M | XXX | $119M | XXX | XXX | XXX |
| EV (current) | $78M | XXX | $78M | XXX | XXX | XXX |
| EV/Revenue | 33.3x | XXX | 1194.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.0x) | XXX | XXX | XXX |
| EV/EBIT | (0.9x) | XXX | (0.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 42.0x | XXX | — | XXX | XXX | XXX |
| P/E | (1.4x) | XXX | (1.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Inovio Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Inovio Pharmaceuticals Margins & Growth Rates
Inovio Pharmaceuticals' revenue in the last 12 month grew by 880%.
Inovio Pharmaceuticals' revenue per employee in the last FY averaged $0.0M.
Inovio Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 880% | XXX | 16558% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (125426%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (21%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1418% | XXX | 50014% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2275% | XXX | 82957% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 132971% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Inovio Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ovid Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioceltix | XXX | XXX | XXX | XXX | XXX | XXX |
| Equillium | XXX | XXX | XXX | XXX | XXX | XXX |
| Cantargia | XXX | XXX | XXX | XXX | XXX | XXX |
| StemRIM | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inovio Pharmaceuticals M&A Activity
Inovio Pharmaceuticals acquired XXX companies to date.
Last acquisition by Inovio Pharmaceuticals was on XXXXXXXX, XXXXX. Inovio Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Inovio Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInovio Pharmaceuticals Investment Activity
Inovio Pharmaceuticals invested in XXX companies to date.
Inovio Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Inovio Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Inovio Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Inovio Pharmaceuticals
| When was Inovio Pharmaceuticals founded? | Inovio Pharmaceuticals was founded in 1983. |
| Where is Inovio Pharmaceuticals headquartered? | Inovio Pharmaceuticals is headquartered in United States. |
| How many employees does Inovio Pharmaceuticals have? | As of today, Inovio Pharmaceuticals has over 134 employees. |
| Who is the CEO of Inovio Pharmaceuticals? | Inovio Pharmaceuticals' CEO is Jacqueline E. Shea. |
| Is Inovio Pharmaceuticals publicly listed? | Yes, Inovio Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Inovio Pharmaceuticals? | Inovio Pharmaceuticals trades under INO ticker. |
| When did Inovio Pharmaceuticals go public? | Inovio Pharmaceuticals went public in 1998. |
| Who are competitors of Inovio Pharmaceuticals? | Inovio Pharmaceuticals main competitors are Ovid Therapeutics, Bioceltix, Equillium, Cantargia. |
| What is the current market cap of Inovio Pharmaceuticals? | Inovio Pharmaceuticals' current market cap is $119M. |
| What is the current revenue of Inovio Pharmaceuticals? | Inovio Pharmaceuticals' last 12 months revenue is $2M. |
| What is the current revenue growth of Inovio Pharmaceuticals? | Inovio Pharmaceuticals revenue growth (NTM/LTM) is 880%. |
| What is the current EV/Revenue multiple of Inovio Pharmaceuticals? | Current revenue multiple of Inovio Pharmaceuticals is 33.3x. |
| Is Inovio Pharmaceuticals profitable? | No, Inovio Pharmaceuticals is not profitable. |
| What is the current net income of Inovio Pharmaceuticals? | Inovio Pharmaceuticals' last 12 months net income is ($83M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.